Skip to Main Content
 

Global Search Box

 
 
 
 

Files

File List


Aguilar Dissertation19.pdf (20.98 MB)

ETD Abstract Container

Abstract Header

Development of A Testicular Cancer Vaccine

Aguilar, Roberto, III
http://rave.ohiolink.edu/etdc/view?acc_num=csu1461270103

Abstract Details

2016, Doctor of Philosophy in Regulatory Biology, Cleveland State University, College of Sciences and Health Professions.
Testicular cancer mainly affects men between the ages of 20 and 35 but is the most common male neoplasm between the ages of 15 and 34. The National Cancer Institute (NCI) states that localized testicular cancer has a recurrence rate of 15-20% and tumors that are Sertoli or Leydig cell derived fail to respond to chemotherapy or radiation treatments. The recurrence rate may increase to 32% if at diagnosis the tumor is greater than 4 cm in size with invasion of the rete testes. To improve therapy for testicular cancer, we examined the usefulness of a testicular cancer vaccine. We reasoned that such a vaccine may strengthen the body’s natural oncologic defenses and assist in the elimination of local and systemic metastases. Also, the vaccine could be administered as adjuvant therapy in conjunction with current standard of care involving surgery and chemotherapy. Inhibin- is a protein involved in spermatogenesis and is secreted by Sertoli and Leydig cells of the testes. Inhibin- is also expressed in many testicular tumors. We found that vaccination against recombinant mouse inhibin- provides protection and therapy against transplantable I-10 mouse testicular tumors in male BALB/c mice. Similarly, we found that vaccination with the immunogenic p215-234 peptide of inhibin- (In 215-234) provides protection and therapy against the growth of autochthonous testicular tumors that grow spontaneously in male SJL.AMH-SV40Tag transgenic mice. Our results provide a rational basis for developing immune control of testicular cancer.
Vincent Tuohy (Advisor)
Girish Shukla (Committee Member)
Barsanjit Mazumder (Committee Member)
William Baldwin (Committee Member)
Xiaoxia Li (Committee Member)
116 p.
Biology; Biomedical Research
cancer vaccine; immunology; testicular cancer

Recommended Citations

Citations

  • Aguilar, III, R. (2016). Development of A Testicular Cancer Vaccine [Doctoral dissertation, Cleveland State University]. OhioLINK Electronic Theses and Dissertations Center. http://rave.ohiolink.edu/etdc/view?acc_num=csu1461270103

    APA Style (7th edition)

  • Aguilar, III, Roberto. Development of A Testicular Cancer Vaccine . 2016. Cleveland State University, Doctoral dissertation. OhioLINK Electronic Theses and Dissertations Center, http://rave.ohiolink.edu/etdc/view?acc_num=csu1461270103.

    MLA Style (8th edition)

  • Aguilar, III, Roberto. "Development of A Testicular Cancer Vaccine ." Doctoral dissertation, Cleveland State University, 2016. http://rave.ohiolink.edu/etdc/view?acc_num=csu1461270103

    Chicago Manual of Style (17th edition)

csu1461270103
571
© 2016, all rights reserved.
This open access ETD is published by Cleveland State University and OhioLINK.